First-in-Class Innovations in Hematological Cancers Discussed by GBI Research in Its Topical Study Available at MarketPublishers.com

21 Jun 2017 • by Natalie Aster

LONDON – The prevalence of lymphoma, myeloma and leukemia is constantly rising, with lymphomas having the highest incidence. Owing to a degree of crossover between different hematological malignancies in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs to test them across numerous indications.

During the past fifteen years, the treatment of hematological malignances has experienced considerable changes, majorly due to the development of targeted therapies. Significant advances have been encouraged by increasing understanding of the signaling pathways engaged in disease pathogenesis.

At present, the hematological cancer pipeline is amid the most innovative in the industry; it includes 477 first-in-class products. The current pipeline focuses on innovative, targeted therapies.

In-demand topical study “Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline” prepared by GBI Research presents a comprehensive assessment of versatile and first-in-class innovation in the world’s hematological cancer pipeline and also sheds light on the major trends in distribution of first-in-class products.

Report Scope:

• all-round analysis of disease diagnosis, pathogenesis, prognosis and therapies;
• overview of the existing unmet needs and possible ways to address them;
• gain a competitive understanding of gaps existing in the present market landscape;
• comprehensive assessment of the hematological cancers pipeline basing on stage of development, molecular type and molecule target;
• info on therapeutic potential of first-in-class targets, assessment of clinical potential of pipeline products and data on the early-stage targets;
• unique data on versatility across the overall pipeline as well as within each molecular target;
• review of versatile activity of each first-in-class product;
• overview of the key commercial opportunities emerging in the hematological cancers marketplace;
• info on the major trends in co-development and licensing deals, and also on hematological cancer therapies that are not already involved in deals, but are considered to offer lucrative investment opportunities;
• etc.

Visit the GBI Research catalogue at MarketPublishers.com to get access to other topical reports prepared by this publisher.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com